Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Name: Kaimen Rigor review — Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Item: Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Rating: 100
Author: Alpha1

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 5★ (Exemplary), 0 critical, 0 high issues for “Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS

Read full text (PMC)

DOI

10.1038/s41591-024-03269-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/29a0d78f-4e91-40b8-917d-58b4a9029933" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/29a0d78f-4e91-40b8-917d-58b4a9029933/badge" alt="Kaimen Rigor review — 5★ (Exemplary), 0 critical, 0 high issues for “Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c7f4cab561d2f8340f66c1faf1809625f455ea45bfb5b22bda66665fbb536ca7

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS

Paper source

Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

01ArithmeticNone found 02OverreachNone found 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 3 trial with clear scientific premise, rigorous design, and transparent reporting. The main weaknesses are minor: lack of explicit CONSORT adherence statement and a few copyedit issues.

Both reviewers classified the study as interventional and agreed on all dimensions. The statistics verification recomputed only 2 tests (HR with CI) and found them consistent; this is a limited check and does not constitute a full validation of all statistics. The citation check found no retracted or non-existent references.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior work (TROPiCS-02) and notes its limitation of few Asian patients, providing a clear rationale for the study. The premise is well-established and the hypothesis follows logically.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study builds on the global TROPiCS-02 trial and clearly identifies the unmet need for data in Asian patients.

Evidence

“TROPiCS-02 primarily enrolled non-Asian patients, with Asian patients making up 3% of the study population . Thus, the benefit–risk profile for SG in Asian patients with HR + HER2 − mBC has not been adequately characterized.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 3]

“The phase 3, randomized EVER-132-002 study ( NCT04639986 ) was initiated to determine the efficacy and safety of SG in Asian patients with endocrine-resistant, pretreated HR + HER2 − mBC.”

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise by citing prior work (TROPiCS-02) and identifying the gap in Asian patients.

Evidence

paraphrase[Introduction, paragraph 3]

“TROPiCS-02 primarily enrolled non-Asian patients, with Asian patients making up 3% of the study population.”

paraphrase[Introduction, paragraph 3]

“The phase 3, randomized EVER-132-002 study (NCT04639986) was initiated to determine the efficacy and safety of SG in Asian patients with endocrine-resistant, pretreated HR+HER2− mBC.”

Randomization method (stratified blocked, block size 4) and unit (patient) are described. Blinding is open-label with a stated limitation. Power analysis is provided. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT and safety populations. Controls are the chemotherapy arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Randomized, open-label, phase 3 trial with adequate randomization, stratification, and sample size calculation.

Evidence

“Patients were randomized via an interactive web-based response system. The randomization list was generated by a designated vendor using stratified blocked randomization with a block size of four.”

MethodsFind in source

“Assuming an HR of 0.70 (median 5.3 versus 3.7 months), approximately 250 PFS events were needed to detect a statistically significant difference between the two groups at a two-sided 0.05 significance level and 80% power.”

Statistical analysisFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“The randomization list was generated by a designated vendor using stratified blocked randomization with a block size of four.”

MethodsFind in source

Statistical analysisFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

Sex is reported (mostly female, with 2 male in chemotherapy). Age is reported. Demographics include region, ECOG PS, visceral metastases, prior therapies. Sex justification is not applicable as both sexes are enrolled. Species/strain/housing are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, and demographics are reported; species/strain/housing are not applicable for a human trial.

Evidence

“Female | 166 (100) | 163 (99) | | Male | 0 | 2 (1) | | Median age (range), years | 53 (32–72) | 51 (28–79)”

Table 1Find in source

paraphrase[Table 1]

“Region, n (%) | Mainland China | 118 (71) | 114 (69) | | Taiwan | 17 (10) | 12 (7) | | Republic of Korea | 31 (19) | 39 (24)”

PASSReviewer 2· 90% conf

Sex, age, and demographics are reported; sex is not justified as single-sex because both sexes are enrolled (though the SG arm is all female).

Evidence

“Female | 166 (100) | 163 (99)”

Table 1Find in source

“Median age (range), years | 53 (32–72) | 51 (28–79)”

Table 1Find in source

The ethics statement names the Declaration of Helsinki and ICH-GCP, and states approval by national regulatory authorities and each site's ethics committee. A list of approving sites is provided. Written informed consent is stated. Regulatory compliance is adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from named committees and written informed consent are documented.

Evidence

“EVER-132-002 was compliant with Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines and was approved by national regulatory authorities, as well as each investigational sites’ ethics committee or review board.”

EthicsFind in source

“All patients gave written informed consent.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethics approval by named ethics committees and written informed consent are documented.

Evidence

EthicsFind in source

“All patients gave written informed consent.”

EthicsFind in source

SG is identified as sacituzumab govitecan with dose and schedule. Chemotherapy options are named. Statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or mycoplasma testing are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (SG) and chemotherapy agents are identified; software is identified.

Evidence

“SG (10 mg kg −1 intravenously days 1 and 8 of every 3 week cycle)”

MethodsFind in source

“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (SG) and chemotherapy agents are identified with dosing; software is identified.

Evidence

paraphrase[Methods, Study design]

“Patients were randomly assigned at 1:1 to receive SG (10 mg kg−1 intravenously days 1 and 8 of every 3 week cycle) or chemotherapy treatment of physician’s choice (eribulin, capecitabine, gemcitabine or vinorelbine, with dosing and schedule per package insert depending on region).”

“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”

Statistical analysisFind in source

Tests named include stratified log-rank, Cox proportional hazards, Cochran-Mantel-Haenszel. Exact p-values are given (e.g., P=0.0028). Effect sizes with 95% CIs are reported. Data presentation includes Kaplan-Meier curves and tables with n. Mathematical plausibility checks were not performed due to lack of raw data; no errors found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, p-values are exact, effect sizes with CIs are reported, and software is identified.

Evidence

“P = 0.0028; median 4.3 versus 4.2 months”

AbstractFind in source

“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, software is identified, and data presentation is adequate for a clinical trial.

Evidence

“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”

ResultsFind in source

“Comparisons of PFS and OS between the treatment groups were performed using a stratified log-rank test (with the three stratification factors used during randomization).”

Statistical analysisFind in source

The data availability statement describes a managed-access process via Gilead with conditions and contact email. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete managed-access route; no code is applicable.

Evidence

“Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting nonconflict of interest.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement provides a concrete managed-access route; repository deposit and accession numbers are not applicable for patient-level data.

Evidence

“To protect the privacy of study participants and proprietary information, Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting nonconflict of interest.”

Data availabilityFind in source

Trial registration number is provided (NCT04639986). Methods are detailed. Limitations are discussed (open-label, small subgroups). Conclusions are proportional to the evidence. Funding (Gilead) and competing interests are disclosed. Reporting guideline is not explicitly mentioned but the paper includes a reporting summary.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier no. NCT04639986”

AbstractFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

“This study is sponsored by Gilead Sciences, Inc.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are complete, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier no. NCT04639986”

AbstractFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 24 verified — 9 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the open-label design and the limited statistical verification as minor caveats; no erratum or correction appears warranted based on this audit.

1.
MEDIUMreporting
Add an explicit statement of adherence to CONSORT guidelines in the Methods or Reporting Summary.
The paper currently does not explicitly name a reporting guideline, which is a minor transparency gap.
2.
MEDIUMreporting
Include a CONSORT flow diagram in the main text or as supplementary material.
A flow diagram improves reporting completeness and is expected for a randomized trial.
3.
MEDIUMdata code
Specify a timeframe for response to data requests in the data availability statement.
Adding a timeline makes the data-sharing route more concrete and actionable.
4.
MEDIUMstatistics
Add a brief statement on how missing data were handled (e.g., censoring rules for PFS/OS) in the statistical analysis section.
Clarifying censoring and missing data handling enhances reproducibility.
5.
MEDIUMreporting
Clarify the role of the sponsor in data analysis and manuscript preparation in the competing interests or acknowledgements.
Transparency about sponsor involvement addresses potential conflicts of interest.
6.
MEDIUMreporting
Report the number of patients with missing Trop-2 H-score in the text rather than only in a table footnote.
Improves transparency about a key biomarker assessment.
7.
MEDIUMreporting
Provide the statistical analysis plan as supplementary material.
Enhances reproducibility and allows readers to verify pre-specified analyses.
8.
LOWcopyedit
Fix the stray parenthesis in the Abstract: 'HR + HER2 − ) metastatic BC (mBC)' should read 'HR + HER2 − metastatic BC (mBC)'.
Typographical error in the abstract.
9.
LOWcopyedit
Add 'at 41 study sites' to the sentence in Results, Patient characteristics for clarity.
Minor clarity improvement.
10.
LOWcopyedit
Clarify the sentence in Table 1 footnote b about prior CDK4/6i duration and mis-stratification.
The sentence is grammatically awkward and could be misinterpreted.
11.
LOWcopyedit
Rephrase the long sentence in Discussion, paragraph 2 about median PFS convergence for clarity.
The sentence is long and could be split for readability.

Full text (58,990 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS

Read full text (PMC)

DOI

10.1038/s41591-024-03269-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/29a0d78f-4e91-40b8-917d-58b4a9029933" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/29a0d78f-4e91-40b8-917d-58b4a9029933/badge" alt="Kaimen Rigor review — 5★ (Exemplary), 0 critical, 0 high issues for “Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c7f4cab561d2f8340f66c1faf1809625f455ea45bfb5b22bda66665fbb536ca7

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

01ArithmeticNone found 02OverreachNone found 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

None found

Checked — nothing surfaced.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study builds on the global TROPiCS-02 trial and clearly identifies the unmet need for data in Asian patients.

Evidence

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 3]

“The phase 3, randomized EVER-132-002 study ( NCT04639986 ) was initiated to determine the efficacy and safety of SG in Asian patients with endocrine-resistant, pretreated HR + HER2 − mBC.”

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise by citing prior work (TROPiCS-02) and identifying the gap in Asian patients.

Evidence

paraphrase[Introduction, paragraph 3]

“TROPiCS-02 primarily enrolled non-Asian patients, with Asian patients making up 3% of the study population.”

paraphrase[Introduction, paragraph 3]

“The phase 3, randomized EVER-132-002 study (NCT04639986) was initiated to determine the efficacy and safety of SG in Asian patients with endocrine-resistant, pretreated HR+HER2− mBC.”

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Randomized, open-label, phase 3 trial with adequate randomization, stratification, and sample size calculation.

Evidence

MethodsFind in source

Statistical analysisFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“The randomization list was generated by a designated vendor using stratified blocked randomization with a block size of four.”

MethodsFind in source

Statistical analysisFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, and demographics are reported; species/strain/housing are not applicable for a human trial.

Evidence

“Female | 166 (100) | 163 (99) | | Male | 0 | 2 (1) | | Median age (range), years | 53 (32–72) | 51 (28–79)”

Table 1Find in source

paraphrase[Table 1]

“Region, n (%) | Mainland China | 118 (71) | 114 (69) | | Taiwan | 17 (10) | 12 (7) | | Republic of Korea | 31 (19) | 39 (24)”

PASSReviewer 2· 90% conf

Sex, age, and demographics are reported; sex is not justified as single-sex because both sexes are enrolled (though the SG arm is all female).

Evidence

“Female | 166 (100) | 163 (99)”

Table 1Find in source

“Median age (range), years | 53 (32–72) | 51 (28–79)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from named committees and written informed consent are documented.

Evidence

EthicsFind in source

“All patients gave written informed consent.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethics approval by named ethics committees and written informed consent are documented.

Evidence

EthicsFind in source

“All patients gave written informed consent.”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (SG) and chemotherapy agents are identified; software is identified.

Evidence

“SG (10 mg kg −1 intravenously days 1 and 8 of every 3 week cycle)”

MethodsFind in source

“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (SG) and chemotherapy agents are identified with dosing; software is identified.

Evidence

paraphrase[Methods, Study design]

“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, p-values are exact, effect sizes with CIs are reported, and software is identified.

Evidence

“P = 0.0028; median 4.3 versus 4.2 months”

AbstractFind in source

“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, software is identified, and data presentation is adequate for a clinical trial.

Evidence

“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”

ResultsFind in source

“Comparisons of PFS and OS between the treatment groups were performed using a stratified log-rank test (with the three stratification factors used during randomization).”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete managed-access route; no code is applicable.

Evidence

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement provides a concrete managed-access route; repository deposit and accession numbers are not applicable for patient-level data.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier no. NCT04639986”

AbstractFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

“This study is sponsored by Gilead Sciences, Inc.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are complete, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier no. NCT04639986”

AbstractFind in source

“One potential limitation of this study is the open-label design.”

Discussion ¶8Find in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 24 verified — 9 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMreporting
Add an explicit statement of adherence to CONSORT guidelines in the Methods or Reporting Summary.
The paper currently does not explicitly name a reporting guideline, which is a minor transparency gap.
2.
MEDIUMreporting
Include a CONSORT flow diagram in the main text or as supplementary material.
A flow diagram improves reporting completeness and is expected for a randomized trial.
3.
MEDIUMdata code
Specify a timeframe for response to data requests in the data availability statement.
Adding a timeline makes the data-sharing route more concrete and actionable.
4.
MEDIUMstatistics
Add a brief statement on how missing data were handled (e.g., censoring rules for PFS/OS) in the statistical analysis section.
Clarifying censoring and missing data handling enhances reproducibility.
5.
MEDIUMreporting
Clarify the role of the sponsor in data analysis and manuscript preparation in the competing interests or acknowledgements.
Transparency about sponsor involvement addresses potential conflicts of interest.
6.
MEDIUMreporting
Report the number of patients with missing Trop-2 H-score in the text rather than only in a table footnote.
Improves transparency about a key biomarker assessment.
7.
MEDIUMreporting
Provide the statistical analysis plan as supplementary material.
Enhances reproducibility and allows readers to verify pre-specified analyses.
8.
LOWcopyedit
Fix the stray parenthesis in the Abstract: 'HR + HER2 − ) metastatic BC (mBC)' should read 'HR + HER2 − metastatic BC (mBC)'.
Typographical error in the abstract.
9.
LOWcopyedit
Add 'at 41 study sites' to the sentence in Results, Patient characteristics for clarity.
Minor clarity improvement.
10.
LOWcopyedit
Clarify the sentence in Table 1 footnote b about prior CDK4/6i duration and mis-stratification.
The sentence is grammatically awkward and could be misinterpreted.
11.
LOWcopyedit
Rephrase the long sentence in Discussion, paragraph 2 about median PFS convergence for clarity.
The sentence is long and could be split for readability.

Full text (58,990 chars)Analyzed: Aug 16, 2026